|
목적 : To evaluate the effect of ranibiaumab administered initially as three loading doses for patients with various stages of retinal angiomatous proliferation (RAP).
방법 : A retrospective chart review of 40 patients (41 eyes) with RAP was conducted. Patients received three initial monthly intravitreal injections (0.5 mg) of ranibizumab and were monitored monthly for 12 months. Reinjection of ranibizumab after three initial monthly doses was administered on as-needed basis. The main outcome measures were the change in the mean of best-corrected Snellen visual acuity (BCVA) and central macular thickness (CMT), and the total number of injections received during the 12 months.
결과 : The mean change in BCVA at 12 months was -0.286, -0.165, and -0.151 (logMAR) in stages I, II, and III, respectively. CMT was also reduced by a mean of 32.72±56.75, 57.45±56.48 and 148.37±98.59 μm. The mean number of treatments was significantly lower in stage I than in later stages (P< 0.001, P < 0.001, and P = 0.15 for stage I versus stage II, stage I versus stage III, and stage II versus stage III, respectively).
결론 : The 12-month follow-up outcomes suggest that three consecutive loading doses of intravitreal ranibizumab is an effective treatment on early stage (stage I) of RAP. Patients in stage I showed a significantly lower recurrence rate than patients in later stages.
|